6887 — Sunshine Lake Pharma Co Income Statement
0.000.00%
Last trade - 00:00- HK$22.99bn
- HK$26.65bn
- CNY4.82bn
Annual income statement for Sunshine Lake Pharma Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 3,814 | 6,386 | 4,019 | 4,815 |
| Cost of Revenue | ||||
| Gross Profit | 2,922 | 5,077 | 3,059 | 3,685 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Other Operating Expenses | ||||
| Total Operating Expenses | 4,607 | 4,620 | 3,638 | 4,145 |
| Operating Profit | -793 | 1,766 | 381 | 670 |
| Total Net Non Operating Interest Income / Expense | ||||
| Net Income Before Taxes | -1,480 | 1,385 | 141 | 440 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -1,416 | 1,014 | 24.8 | 270 |
| Minority Interest | ||||
| Net Income Before Extraordinary Items | ||||
| Net Income | -1,209 | 185 | -207 | 272 |
| Adjustments to Net Income | ||||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -1,085 | 185 | -207 | 272 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -1.58 | — | -0.284 | 0.573 |